The projects that tend to get acqui-hired — Astral, Bun, Cirrus, etc. — share something specific: they solved a real problem that the acquirer depends on internally, and nobody else had solved it well enough. That's a different dynamic than "be notable and hope someone bids."
What's actually happening is that AI labs have infrastructure needs that don't map cleanly onto existing commercial products, so the fastest path to having the tool they want is to bring the team building it in-house. That's closer to procurement than a traditional acqui-hire.
Whether that's net positive for the ecosystem is genuinely unclear. You get a better-resourced tool in the near term. But you also get organizational risk: if the acquirer pivots or the team gets reassigned, the institutional knowledge goes with it. Tart being relicensed more permissively is the hedge against that scenario, and it's a smart move.
What's actually happening is that AI labs have infrastructure needs that don't map cleanly onto existing commercial products, so the fastest path to having the tool they want is to bring the team building it in-house. That's closer to procurement than a traditional acqui-hire.
Whether that's net positive for the ecosystem is genuinely unclear. You get a better-resourced tool in the near term. But you also get organizational risk: if the acquirer pivots or the team gets reassigned, the institutional knowledge goes with it. Tart being relicensed more permissively is the hedge against that scenario, and it's a smart move.